BACKGROUND: Members of the Burkholderia cepacia complex (Bcc) cause considerable morbidity and mortality in patients with chronic granulomatous disease and cystic fibrosis. Many Bcc strains are antibiotic resistant, which requires the exploration of novel antimicrobial approaches, including antisense technologies such as phosphorodiamidate morpholino oligomers (PMOs). METHODS: Peptide-conjugated PMOs (PPMOs) were developed to target acpP, which encodes an acyl carrier protein (AcpP) that is thought to be essential for growth. Their antimicrobial activities were tested against different strains of Bcc in vitro and in infection models. RESULTS: PPMOs targeting acpP were bactericidal against clinical isolates of Bcc (>4 log reduction), whereas a PPMO with a scrambled base sequence (scrambled PPMO) had no effect on growth. Human neutrophils were infected with Burkholderia multivorans and treated with AcpP PPMO. AcpP PPMO augmented killing, compared with neutrophils alone and compared with neutrophils alone plus scrambled PPMO. Mice with chronic granulomatous disease that were infected with B. multivorans were treated with AcpP PPMO, scrambled PPMO, or water at 0, 3, and 6 h after infection. Compared with water-treated control mice, the AcpP PPMO-treated mice showed an approximately 80% reduction in the risk of dying by day 30 of the experiment and relatively little pathology. CONCLUSION: AcpP PPMO is active against Bcc infections in vitro and in vivo.
BACKGROUND: Members of the Burkholderia cepacia complex (Bcc) cause considerable morbidity and mortality in patients with chronic granulomatous disease and cystic fibrosis. Many Bcc strains are antibiotic resistant, which requires the exploration of novel antimicrobial approaches, including antisense technologies such as phosphorodiamidate morpholino oligomers (PMOs). METHODS:Peptide-conjugated PMOs (PPMOs) were developed to target acpP, which encodes an acyl carrier protein (AcpP) that is thought to be essential for growth. Their antimicrobial activities were tested against different strains of Bcc in vitro and in infection models. RESULTS: PPMOs targeting acpP were bactericidal against clinical isolates of Bcc (>4 log reduction), whereas a PPMO with a scrambled base sequence (scrambled PPMO) had no effect on growth. Human neutrophils were infected with Burkholderia multivorans and treated with AcpP PPMO. AcpP PPMO augmented killing, compared with neutrophils alone and compared with neutrophils alone plus scrambled PPMO. Mice with chronic granulomatous disease that were infected with B. multivorans were treated with AcpP PPMO, scrambled PPMO, or water at 0, 3, and 6 h after infection. Compared with water-treated control mice, the AcpP PPMO-treated mice showed an approximately 80% reduction in the risk of dying by day 30 of the experiment and relatively little pathology. CONCLUSION:AcpP PPMO is active against Bcc infections in vitro and in vivo.
Authors: Leslie A Kalish; David A Waltz; Mark Dovey; Gail Potter-Bynoe; Alexander J McAdam; John J Lipuma; Craig Gerard; Donald Goldmann Journal: Am J Respir Crit Care Med Date: 2005-11-04 Impact factor: 21.405
Authors: J D Pollock; D A Williams; M A Gifford; L L Li; X Du; J Fisherman; S H Orkin; C M Doerschuk; M C Dinauer Journal: Nat Genet Date: 1995-02 Impact factor: 38.330
Authors: Erin K Sully; Bruce L Geller; Lixin Li; Christina M Moody; Stacey M Bailey; Amy L Moore; Michael Wong; Patrice Nordmann; Seth M Daly; Carolyn R Sturge; David E Greenberg Journal: J Antimicrob Chemother Date: 2017-03-01 Impact factor: 5.790
Authors: Donna Wesolowski; Hyun Seop Tae; Neeru Gandotra; Paula Llopis; Ning Shen; Sidney Altman Journal: Proc Natl Acad Sci U S A Date: 2011-09-26 Impact factor: 11.205
Authors: Cesar de la Fuente-Nunez; Marcelo Dt Torres; Francisco Jm Mojica; Timothy K Lu Journal: Curr Opin Microbiol Date: 2017-06-14 Impact factor: 7.934
Authors: David E Greenberg; Daniel E Sturdevant; Kimberly R Marshall-Batty; Jessica Chu; Anthony M Pettinato; Kimmo Virtaneva; John Lane; Bruce L Geller; Stephen F Porcella; John I Gallin; Steven M Holland; Kol A Zarember Journal: Infect Immun Date: 2015-08-17 Impact factor: 3.441